Point of Care Testing | Nanogen | Rapid Testing Solutions

Medical professionals can establish a higher point-of-care testing standard when they institute rapid testing in urgent care situations. Rapid tests allow healthcare providers to more quickly diagnose disease which leads to better, and more cost effective, patient care and management.

Doctors, lab technicians, nurses, hospital management, and most importantly, patients, benefit from simplified membrane based technology that is rapid, reliable and easy to use. Nanogen offers rapid testing products to aid in the diagnosis of cardiovascular disease by testing levels of biomarkers such as NT-proBNP, D-Dimer, Troponin I, Myoglobin, and/or CK-MB. Nanogen is dedicated to ensuring that you have not only the right point-of-care diagnostics and rapid testing tools, but also the right processes in place to make significant enhancements to your decentralized testing protocols.

Unable to display object 'solutions product list' correctly!
Details: Operation is not allowed when the object is closed.

	Vyent™* Vyent, quantitative cardiac tests based on whole blood and/or EDTA plasma, present healthcare providers with reliable rapid testing solutions for urgent care. The Vyent product pipeline includes quick and accurate tests to aid in the diagnosis of several cardiovascular diseases including congestive heart failure (CHF), myocardial infarction (MI), acute coronary syndrom (ACS), disseminated intravascular coagulation (DIC), and venous thromboembolism (VTE). Nanogen's CE marked Vyent NT-proBNP* test aids in the diagnosis of CHF by testing NT-proBNP levels and is intended for use with the DXpress™ Reader.

	Cardiac STATus® Cardiac STATus, a rapid biomarker test, delivers trusted qualitative results that translate to better diagnostic decision at the point of care for myocardial infarction and cardiovascular disease. Nanogen offers Cardiac STATus in two configurations: as a stand alone Troponin I test and as a combination of Troponin I, Myoglobin and CK-MB.

	Decision Point™ Decision Point, CE marked and available only outside the US, quickly and accurately uses biomarkers to aid in the diagnosis of acute myocardial infarction in patients experiencing chest pain. Delivering qualitative results, Decision Point is offered in two configurations: as a stand alone Troponin I test and as a combination of Troponin I, Myoglobin and CK-MB. *CE marked. Anticipating FDA clearance in 2009.